SCHEMBL1275138

SCHEMBL1275138

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.75
DNPH1 O43598 1/20 0.75
PRKAB2 O43741 1/20 0.75
TRPM2 O94759 1/20 0.75
LDHA P00338 1/20 0.75
ADRB2 P07550 1/20 0.75
FBP1 P09467 1/20 0.75
SRC P12931 1/20 0.75
P2RY2 P41231 1/20 0.75
P2RY1 P47900 1/20 0.75
PRKAG1 P54619 1/20 0.75
PRKAA2 P54646 1/20 0.75
PDE4D Q08499 1/20 0.75
KCNH2 Q12809 1/20 0.75
PRKAA1 Q13131 1/20 0.75
PDE3A Q14432 1/20 0.75
SMN1; SMN2 Q16637 1/20 0.75
TAS1R3 Q7RTX0 1/20 0.75
TAS1R1 Q7RTX1 1/20 0.75
P2RY11 Q96G91 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23647917 1.00 ADORA1 (0.75) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL9990451 1.00 ADORA1 (0.75) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL29388941 1.00 ADORA1 (0.75) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL20942825 1.00 ADORA1 (0.75) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL29496215 0.96 P2RY1 (0.80) ADORA1DNPH1PRKAB2TRPM2LDHA
Adenosine Phosphate SCHEMBL3828789 0.90 P2RY1 (0.92) ADORA1DNPH1PRKAB2TRPM2LDHA
SCHEMBL3694223 0.90 ADORA3 (0.76) ADORA1SMN1; SMN2
SCHEMBL25413594 0.90 ADORA3 (0.76) ADORA1SMN1; SMN2
SCHEMBL29796608 0.90 ADORA3 (0.76) ADORA1SMN1; SMN2
SCHEMBL3694227 0.90 ADORA3 (0.76) ADORA1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9249473-B2 Compositions and methods for the identification of inhibitors of retroviral infection Trana Discover, Inc. (US) 2016-02-02 US claimed
US-20140121124-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION GUENTHER RICHARD H (US) 2014-05-01 US claimed
EP-2201118-B1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION TRANA DISCOVERY (US) 2012-04-18 EP claimed
US-20100291032-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION TRANA DISCOVERY (US) 2010-11-18 US claimed
EP-2201118-A2 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION Trana Discovery (US) 2010-06-30 EP claimed
WO-2009036299-A2 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION TRANA DISCOVERY (US) 2009-03-19 WO claimed
WO-2024148237-A1 SCREENING METHODS FOR IDENTIFYING SPECIFIC INHIBITORS OF MYCOBACTERIA, INCLUDING M. TUBERCULOSIS TRANA DISCOVERY, INC. (US) 2024-07-11 WO disclosed
US-10316371-B2 Screening methods for identifying specific Staphylococcus aureus inhibitors TRANA DISCOVERY, INC. (US) 2019-06-11 US disclosed
US-20190024152-A1 IDENTIFICATION OF SELECTED SPECTRUM ANTIBIOTICS TRANA DISCOVERY, INC. (US) 2019-01-24 US disclosed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 US disclosed
US-9877956-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-01-30 US disclosed
US-9677143-B2 Compositions and methods for the identification of inhibitors of retroviral infection TRANA DISCOVERY, INC. (US) 2017-06-13 US disclosed
US-20080199870-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS TRANA DISCOVERY, INC. 2008-08-21 US disclosed
EP-1944321-A2 Methods and compositions for determining the purity of chemically synthesized nucleic acids North Carolina State University (US) 2008-07-16 EP disclosed
WO-2008064304-A9 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS TRANA DISCOVERY INC (US) 2008-07-10 WO disclosed
WO-2008064304-A2 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS TRANA DISCOVERY, INC. (US) 2008-05-29 WO disclosed
US-6962785-B2 Antibacterial and antiviral agents and methods of screening for the same NORTH CAROLINA STATE UNIVERSITY (US) 2005-11-08 US disclosed
US-6929907-B2 Used for detecting incomplete deprotection of a synthetic oligonucleotide by immunoassay NORTH CAROLINA STATE UNIVERSITY (US) 2005-08-16 US disclosed
US-6461815-B1 DETERMINATION IF DRUG INHIBITS BINDING OF TDNA TO RIBOSOME NORTH CAROLINA STATE UNIVERSITY 2002-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316371-B2 Screening methods for identifying specific Staphylococcus aureus inhibitors NSUN3, RNGTT, TRMT1 ADORA1 2579/4885DNPH1 3432/4885PRKAB2 3018/4885
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 ADORA1 2791/4885DNPH1 3165/4885PRKAB2 4480/4885
US-20100291032-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION TRMT1L, TRMT1, TARBP1 ADORA1 2198/4885DNPH1 4171/4885PRKAB2 4120/4885
US-20080199870-A1 COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS NSUN3, RNGTT, TARBP1 ADORA1 4078/4885DNPH1 2127/4885PRKAB2 1666/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 ADORA1 2791/4885DNPH1 3165/4885PRKAB2 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.